Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents

Junya Lv; Lijuan Xing; Xin Zhong; Kai Li; Mingyan Liu; Ke Du

Biomedicine & Pharmacotherapy (Jun 2023)

Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents

Junya Lv,
Lijuan Xing,
Xin Zhong,
Kai Li,
Mingyan Liu,
Ke Du

Affiliations

Junya Lv: School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China
Lijuan Xing: Precision Laboratory of Panjin Central Hospital, Panjin 124000, China
Xin Zhong: School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China
Kai Li: Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, the First Affiliated Hospital of China Medical University, Shenyang 110001, China; Corresponding author.
Mingyan Liu: School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China; Liaoning Medical Diagnosis and Treatment Center, Shenyang 110179, China; Corresponding authors at: School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China.
Ke Du: School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China; Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, the First Affiliated Hospital of China Medical University, Shenyang 110001, China; Liaoning Medical Diagnosis and Treatment Center, Shenyang 110179, China; Corresponding authors at: School of Pharmacy, Department of Pharmacology, China Medical University, Shenyang 110122, China.

Journal volume & issue: Vol. 162
p. 114583

Abstract

Read online

N6-methyladenosine (m6A) is a ubiquitous mRNA modification in eukaryotes. m6A occurs through the action of methyltransferases, demethylases, and methylation-binding proteins. m6A methylation of RNA is associated with various neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), depression, cerebral apoplexy, brain injury, epilepsy, cerebral arteriovenous malformations, and glioma. Furthermore, recent studies report that m6A-related drugs have attracted considerable concerns in the therapeutic areas of neurological disorders. Here, we mainly summarized the role of m6A modification in neurological diseases and the therapeutic potential of m6A-related drugs. The aim of this review is expected to be useful to systematically assess m6A as a new potential biomarker and develop innovative modulators of m6A for the amelioration and treatment of neurological disorders.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords